Identity
- Security key
- 11167
- Ticker
- AARD
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2025-02-13
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- AARD
Detail
Enriched 2026-08-14 20:47
- Market cap
- $143,783,438.22
- Shares outstanding (class)
- 21,884,158
- Shares outstanding (weighted)
- 21,884,846
- SIC
- 2834 PHARMACEUTICAL PREPARATIONS
- Employees
- 28
- Location
- SAN DIEGO, CA
- Description
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.